E
PharmaCielo Ltd. PCLOF
$0.0478 -$0.0067-12.29%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
E
Sell 4/21/2023Downgrade
PharmaCielo Ltd. (PCLOF) was downgraded to E+ from D- on 4/21/2023 due to a decline in the volatility index, valuation index and total return index.
D
Sell 4/6/2023Upgraded
PharmaCielo Ltd. (PCLOF) was upgraded to D- from E+ on 4/6/2023 due to an increase in the total return index and volatility index.
E
Sell 3/14/2023Downgrade
PharmaCielo Ltd. (PCLOF) was downgraded to E+ from D on 03/14/2023.
D
Sell 2/9/2023Upgraded
PharmaCielo Ltd. (PCLOF) was upgraded to D from E+ on 02/09/2023.
E
Sell 2/8/2023Downgrade
PharmaCielo Ltd. (PCLOF) was downgraded to E+ from D on 2/8/2023 due to a noticeable decline in the solvency index, total return index and volatility index. The quick ratio declined from 1.36 to 0.09, and debt to equity increased from 0.7 to 1.32.
D
Sell 5/16/2022Upgraded
PharmaCielo Ltd. (PCLOF) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index and total return index.
E
Sell 5/13/2022Downgrade
PharmaCielo Ltd. (PCLOF) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell 5/4/2022Upgraded
PharmaCielo Ltd. (PCLOF) was upgraded to D from E+ on 5/4/2022 due to an increase in the valuation index, growth index and solvency index.
E
Sell 5/1/2022Downgrade
PharmaCielo Ltd. (PCLOF) was downgraded to E+ from D on 5/1/2022 due to a decline in the valuation index and solvency index. Debt to equity increased from 0.13 to 0.38.
D
Sell 4/21/2022Upgraded
PharmaCielo Ltd. (PCLOF) was upgraded to D from E+ on 04/21/2022.
E
Sell 4/20/2022Downgrade
PharmaCielo Ltd. (PCLOF) was downgraded to E+ from D on 4/20/2022 due to a large decline in the total return index and solvency index. The quick ratio declined from 1.35 to 0.72, and debt to equity increased from 0.1 to 0.13.
D
Sell 11/9/2021Upgraded
PharmaCielo Ltd. (PCLOF) was upgraded to D from E+ on 11/09/2021.
E
Sell 11/8/2021Downgrade
PharmaCielo Ltd. (PCLOF) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index, growth index and solvency index. Total revenue declined 31.93% from $533.4 to $363.1, and earnings per share declined from -$0.0371 to -$0.0402.
D
Sell 12/29/2020Upgraded
PharmaCielo Ltd. (PCLOF) was upgraded to D from D- on 12/29/2020 due to an increase in the volatility index and total return index.
D
Sell 12/1/2020Downgrade
PharmaCielo Ltd. (PCLOF) was downgraded to D- from D on 12/1/2020 due to a decline in the valuation index, growth index and solvency index. Total revenue declined 97.81% from $889.9 to $19.5, operating cash flow declined 38.16% from -$3.92M to -$5.42M, and the quick ratio declined from 1.4 to 0.97.
D
Sell 11/9/2020Upgraded
PharmaCielo Ltd. (PCLOF) was upgraded to D from D- on 11/9/2020 due to an increase in the volatility index and total return index.
D
Sell 10/21/2020Downgrade
PharmaCielo Ltd. (PCLOF) was downgraded to D- from D on 10/21/2020 due to a decline in the volatility index.
D
Sell 10/5/2020Upgraded
PharmaCielo Ltd. (PCLOF) was upgraded to D from D- on 10/5/2020 due to an increase in the volatility index.
D
Sell 9/18/2020Downgrade
PharmaCielo Ltd. (PCLOF) was downgraded to D- from D on 9/18/2020 due to a large decline in the solvency index, growth index and volatility index. The quick ratio declined from 1.65 to 1.4, earnings per share declined from -$0.0475 to -$0.0532, and operating cash flow declined 8.24% from -$3.62M to -$3.92M.
D
Sell 6/2/2020Upgraded
PharmaCielo Ltd. (PCLOF) was upgraded to D from D- on 6/2/2020 due to a major increase in the growth index. Earnings per share increased from -$0.0961 to -$0.0521, and EBIT increased 44.77% from -$9.35M to -$5.16M.
D
Sell 4/23/2020Upgraded
PharmaCielo Ltd. (PCLOF) was upgraded to D- from E+ on 4/23/2020 due to an increase in the volatility index.
E
Sell 3/18/2020Downgrade
PharmaCielo Ltd. (PCLOF) was downgraded to E+ from D- on 3/18/2020 due to a decline in the volatility index and total return index.
D
Sell 3/3/2020Upgraded
PharmaCielo Ltd. (PCLOF) was upgraded to D- from E+ on 3/3/2020 due to a large increase in the solvency index, valuation index and growth index. Earnings per share increased from -$0.083 to -$0.0299, and EBIT increased 59.03% from -$7.6M to -$3.12M.
E
Sell 10/1/2019Upgraded
PharmaCielo Ltd. (PHCEF) was upgraded to E+ from E on 10/1/2019 due to an increase in the valuation index.
E
Sell 7/1/2019Upgraded
PharmaCielo Ltd. (PHCEF) was upgraded to E from E- on 7/1/2019 due to an increase in the valuation index.
E
Sell 5/31/2019None
PharmaCielo Ltd. (PCLOF) was downgraded to E- from U on 05/31/2019.
Weiss Ratings